News and blogs
353 results found.
New blood cancer drugs in Scotland approved
Regulators in Scotland, has approved two new blood cancer treatments for use on the NHS in Scotland. A CAR-T therapy for diffuse large B-cell lymphoma is one of the treatments.
24 hour clubathon raises funds for friend on the Wirral
Friends from Wallasey, on the Wirral, will host a special 24-hour Clubathon event in support of one of their close-knit community Laura Parker, 35, who has an aggressive leukaemia, a form of blood cancer.
Interferon supplies for people with MPNs (Pegasys)
Find out what Blood Cancer UK is doing to solve the UK shortage of pegylated interferon alfa 2a (Pegasys), and what you can do if you take Pegasys to treat an MPN.
New life-changing myeloma drug given positive recommendation for fourth-line use on the NHS for those ‘exhausting’ options
The drug teclistamab (Tecvayli), has been recommended by NICE to treat myeloma, a form of blood cancer, in England and Wales.
Why at Blood Cancer UK we think the new investment towards improving cancer detection from the government is promising
The government has announced a number of new partnerships backed by public and private sector investment to tackle cancer and other life-threatening diseases with faster diagnoses and better treatments, deploying innovative technologies and approaches.
Dr Jewel Cobb – cancer researcher and champion of equality
Dr Jewel Plummer Cobb was an African American cell biologist and physiologist who contributed to pioneering research into cancer treatment.
A step forward for people with blood cancer
The drug quizartinib is now available for people with this specific form of blood cancer on the NHS in England.
World Cancer Research Day: our new research projects
We are funding eight new research projects we are funding taking our total number of research projects to 87 across the UK.
Mpox (monkeypox) and blood cancer
Find out about mpox, how it spreads, signs and symptoms, cases in the UK, and what it means for people with blood cancer.
Our Blood Cancer Action Plan to tackle blood cancer survival in the UK
Blood Cancer UK releases its comprehensive Action Plan "Taking blood cancer out of the shadows: A plan to increase survival in the UK"
Wales lags behind England in blood cancer survival
Our press release on our Blood Cancer Action Plan reveals how Wales is lagging behind England when it comes to blood cancer survival. Our landmark report is available to download in English and Welsh.
Ellie's blood cancer story
Ellie lived with acute myeloid leukaemia (AML). Her family are encouraging people to donate towards life-saving research.
Take at home tablet approved for blood cancer on NHS England
Zanubrutinib, is now available on the NHS in England for those with a type of blood cancer called marginal zone lymphoma.,
Drug, dasatinib approved for use on the NHS in Scotland
Dasatinib, is now approved for the treatment of adults with a form of leukaemia - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) - on the NHS in Scotland.
New class of drug approved for myeloma in England and Wales
The very first bispecific drug for myeloma, elranatamab has been approved for restricted use in England and Wales as a fourth-line treatment.
New blood test for myeloma being researched at Birmingham
Two doctors at the University of Birmingham are developing a new technique to help diagnose and monitor people with the blood cancer, non-measurable myeloma.
Scotland approves two new blood cancer drugs
Two new drugs for the blood cancer, diffuse large B-cell lymphoma DLBCL have been made available for use on the NHS in Scotland as a third-line treatment.
Blood cancer treatment for a form of acute myeloid leukaemia approved for use on NHS
New blood cancer treatment for acute myeloid leukaemia (AML) with IDH1 mutation. The National Institute for Health and Care Excellence (NICE) approved Ivosidenib (Tibsovo) with azacitidine has made it available to those in England and Wales.
What's the latest evidence regarding COVID-19 vaccines and blood cancer?
Lots of information continues to circulate about COVID-19 and vaccinations for immunocompromised people. Blood Cancer UK’s Healthcare Professional Advisory Panel (HPAP), made up of specialists from across the UK working in haemato-oncology and related professional fields, has released the statement below to help you understand the latest evidence.
One year later – are we still on track?
Back in 2022, Blood Cancer UK created a new five-year strategy. We made a commitment back then to shape that strategy alongside the Blood Cancer UK community, and to give regular updates. We're now at the end of year one, so it’s the perfect time to stop, reflect and consider whether we're on track.
